Atlas FRM’s Darling Ingredients DAR Stock Holding History

Atlas FRM’s Portfolio DAR Stock Details DAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200,000	Closed	-$9.97M	–	9
2023 Q4	$9.97M	Hold	200,000	–	–	1.72%	8
2023 Q3	$10.4M	Hold	200,000	–	–	1.72%	9
2023 Q2	$12.8M	Hold	200,000	–	–	2.44%	8
2023 Q1	$11.7M	Hold	200,000	–	–	2.33%	6
2022 Q4	$12.5M	Buy	+200,000	New	+$14.1M	2.43%	6

Other funds holding DAR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Atlas FRM's DAR Position: Q1 2024 in Review

Atlas FRM sold out of Darling Ingredients (DAR) in Q1 2024, closing a stake of 200,000 shares — an estimated $9.97M sold.

Atlas FRM first reported a position in DAR in Q4 2022 and held it in 5 quarters. The position peaked at $12.8M in Q2 2023. 519 funds tracked by Wall St. Rank hold DAR as of Q1 2024.

Atlas FRM reported no remaining Darling Ingredients position as of Q1 2024 after selling out during the quarter.
Atlas FRM sold 200,000 Darling Ingredients shares in Q1 2024, an estimated $9.97M.
Atlas FRM first reported a position in Darling Ingredients in Q4 2022 and held it in 5 quarters.
Atlas FRM's Darling Ingredients position peaked at $12.8M in Q2 2023.
519 funds tracked by Wall St. Rank held Darling Ingredients as of Q1 2024.

Based on Atlas FRM's 13F filing for Q1 2024, filed 14 May 2024.